AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 57 min read$NAMS

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results – Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q20

Original reporting
SEC EDGAR 8-K
Published Aug 5, 2026, 11:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 11:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$NAMS
Bullish
high confidence
Mentioned
$NAMS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NAMSBullishMed
01

Why it matters

The newest actionable items are the CHMP positive opinion for marketing authorization in Europe and reiterated timelines for PREVAIL interim analysis (4Q2026) and RUBENS topline (by year-end 2026), plus planned additional analyses throughout 2026.

02

Market read

Traders get a fresh regulatory milestone plus a calendar of upcoming clinical catalysts, which can drive probability re-pricing ahead of the European Commission decision and later 2026 data.

03

What to watch

Cash balance declines quarter-over-quarter, and the most market-moving datapoints (PREVAIL interim and RUBENS topline) are still months away, limiting immediate rerating durability.

Relevance 7/10Novelty 7/10Timing: Investor Day today at 9:00 AM ET, with regulatory and clinical milestones reiterated.

Background

SEC Form 8-K Item 2.02 with corporate update and Q2 2026 financial results for NewAmsterdam Pharma.

Company-level read

Ticker impact

$NAMSBullishHigh confidence
Context

NewAmsterdam reports a positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe, plus multiple late-stage milestones.

Expected impact

Near-term upside bias as traders price the European Commission decision timing and upcoming PREVAIL interim results.

Evidence & confidence

The filing is a primary SEC 8-K with a concrete regulatory milestone (CHMP positive opinion) and specific upcoming data timelines (PREVAIL interim in 4Q2026, RUBENS topline by year-end 2026).

Market effects

Sector

Strengthens sentiment for late-stage lipid-lowering CETP inhibitor programs and for non-statin LDL-C therapies in development.

Regional

Europe-focused regulatory progress may shift expectations for timelines of cholesterol drug approvals via EMA/European Commission.

Global

Could influence global read-across for CETP inhibition efficacy and safety narratives across CV and early Alzheimer’s indications.

Counterpoint

What could challenge this read

A CHMP positive opinion is not the final European Commission decision, so the market may over-discount near-term approval odds.

Key entities

  • issuer
    NewAmsterdam Pharma Company N.V.

    Late-stage clinical biopharmaceutical developing obicetrapib (CETP inhibitor) as monotherapy and with ezetimibe.

  • regulator
    CHMP (EMA)

    Committee for Medicinal Products for Human Use issuing a positive opinion recommending marketing authorization.

  • regulator
    European Commission

    Expected to issue the final decision later in 2026.

  • clinical_trial
    PREVAIL

    Phase 3 CV outcomes trial evaluating obicetrapib in ASCVD patients with uncontrolled LDL-C.

  • clinical_trial
    RUBENS

    Phase 3 trial in type 2 diabetes or metabolic syndrome patients, with topline expected by year-end 2026.

Read at source← All news

Related articles

SEP 29
$NAMSLowAI 8/10

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease - SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeabl

SEC EDGAR 8-K1 min
SEP 23
$NAMSMedAI 9/10

Is NewAmsterdam Pharma (NAMS) Undervalued After Its First Obicetrapib Approval?

NewAmsterdam Pharma (NAMS) received European Commission approval for its cholesterol drug obicetrapib, marking its first global regulatory approval. The stock has seen a recent bounce, up 3.28% to $23.32, following a period of decline. Analysts suggest the company may be undervalued with an implied fair value of $50.92, but risks include potential trial failures and equity dilution.

simplywall.st2 min
SEP 21
$NAMSMedAI 8/10

NewAmsterdam Pharma Company N.V. along with its partner Menarini Group announced that the European Commission has granted marketing authorization for Ubeslo…

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 21, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) along with its partner Menarini Group (“Menarini”) announced that the European Commission (“EC”) has granted marketing authorization for Ubeslo ® (obicetrapib 10 mg monotherapy) and Ev

SEC EDGAR 8-K2 min
JUL 24
$NAMSMed

NewAmsterdam, Menarini Cholesterol Drugs Receive Positive Opinion From CHMP

NewAmsterdam Pharma (NAMS) and Menarini said the EMA CHMP issued a positive opinion for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for adults with primary hypercholesterolemia. CHMP based on Phase 3 BROADWAY, BROOKLYN and TANDEM; LDL-C fell up to 40% with monotherapy and about 50% with the combo vs placebo. European Commission decision expected H2 2026.

rttnews.com3 min